Seeking to put a lid on rising drug prices, U.S. Sen. Ron Wyden has introduced a bill that would require drug makers to justify hefty price hikes, a move that resembles legislation being introduced in a growing number of state legislatures around the country.
In this instance, the U.S. Department of Health and Human Services would track increases in list prices and notify manufacturers when those prices exceed certain benchmarks. At that point, drug makers would have to justify the increases — and may also have to provide information on R&D funding and marketing costs — or they can lower their prices.
Any of these sounds like a more real solution than the latest proposed ‘Executive Order’ – see Little, June 14, 2017.
Comments are closed.